Kymera Therapeutics, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$1.32. It usually reports 13–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Jan 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 13–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
-100.0%
|
-132
-60.6%
|
-1.32
-40.4%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
65
+466.4%
|
-61
+20.1%
|
-0.62
+34.7%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
34
+55.5%
|
-69
-5.6%
|
-0.71
+13.4%
|
|
Jan 13, 2026
13 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3
-61.2%
|
-87
-22.9%
|
-0.97
-9.5%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
-26.1%
|
-82
-31.5%
|
-0.94
-14.6%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
-55.3%
|
-77
-82.1%
|
-0.95
-63.8%
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
22
+114.8%
|
-66
-35.1%
|
-0.82
-18.8%
|
|
Jan 14, 2025
14 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
7
-84.6%
|
-71
-392.4%
|
-0.88
-259.6%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1815442
- Former names
- Kymera Therapeutics, Inc. (until Oct 29, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.